Buy or sell Synergy Pharmaceuticals stock pre IPO via an EquityZen fund
Synergy Pharmaceuticals Stock
Synergy Pharmaceuticals is a biopharmaceutical company developing novel therapies for the treatment of gastrointestinal conditions.
About Synergy Pharmaceuticals Stock
Synergy Pharmaceuticals Inc., headquartered in New York, NY with laboratories in Doylestown, PA, is a biopharmaceutical company focused on the research and development of novel therapies for the treatment of chronic idiopathic constipation, irritable bowel syndrome with constipation and other difficult-to-treat gastrointestinal (GI) conditions. Synergy’s lead drug, plecanatide, and next-generation candidate, SP-333, are proprietary analogs of the natural human GI hormone, uroguanylin, and members of the new class of guanylate cyclase-C (“GC-C”) agonists.
President & CEO
Gary S. Jacob
Patrick H. Griffin
Synergy Pharmaceuticals Moves Forward on Path Toward Sale
Wall Streets Journal - Dec, 14 2018